GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT

Pharmaceutical giant GSK has agreed to buy US cancer drug firm Nuvalent in a 10.6 billion US dollar (£8 billion) deal as it looks to expand its cancer treatment offering.

It marks a significant expansion of GSK’s cancer portfolio, which has been slowly growing since the British drugmaker returned to the disease space in 2019, as well as the first major acquisition for Chief Executive Officer Luke Miels.

Representatives for GSK and Nuvalent did not respond to CNBC's requests for comment.

The transaction notably includes three lung cancer products: Zidesamtinib, Neladalkib, and NVL-330.